Diakonos Oncology Appoints Dr. Laura Aguilar as Chief Medical Officer
Slice of Healthcare Team
Nov 21, 2024
Key Highlights
- Dr. Laura Aguilar named Chief Medical Officer at Diakonos Oncology.
- DOC1021 dendritic cell vaccine to enter Phase 2 clinical trial for glioblastoma (GBM).
- Deancy Okoebor and Eva Highberg Schumann join clinical operations team.
- FDA Fast Track and Orphan Drug Designation for GBM program secured.
Source: Business Wire
Notable Quotes
“ I believe Diakonos’ dendritic cell vaccines may represent a first-of-its-kind strategy for engaging a complete immune response to attack cancer. ”
Dr. Laura Aguilar, M.D., Ph.D. – Chief Medical Officer at Diakonos Oncology
“ Her entrepreneurial background, clinical development expertise, and physician-patient experience will be essential in advancing our pipeline of highly differentiated dendritic cell vaccines. ”
Mike Wicks, CEO at Diakonos Oncology
